digplanet beta 1: Athena
Share digplanet:

Agriculture

Applied sciences

Arts

Belief

Business

Chronology

Culture

Education

Environment

Geography

Health

History

Humanities

Language

Law

Life

Mathematics

Nature

People

Politics

Science

Society

Technology

Lennox–Gastaut syndrome
Classification and external resources
ICD-10 G40.4
ICD-9 345.0
DiseasesDB 29493
eMedicine neuro/186
Patient UK Lennox–Gastaut syndrome

Lennox–Gastaut syndrome (LGS), also known as Lennox syndrome, is a difficult-to-treat form of childhood-onset epilepsy that most often appears between the second and sixth year of life, and is characterized by frequent seizures and different seizure types; it is often accompanied by developmental delay and psychological and behavioral problems.

Characteristics[edit]

As a general rule, the age of seizure onset in LGS patients is between the ages of two and six; however, this does not exclude the possibility that seizures can begin before age two, or after age six. The syndrome shows clear parallels to West syndrome, enough to suggest a connection.

Daily multiple seizures are typical in LGS. Also typical is the broad range of seizures that can occur, larger than that of any other epileptic syndrome. The most frequently occurring seizure type is tonic seizures, which are often nocturnal (90%); the second most frequent are myoclonic seizures, which often occur when the person is over-tired.[1]

Atonic, atypical absence, tonic, complex partial, focalized and tonic–clonic seizures are also common. Additionally, about half of patients will have status epilepticus, usually the nonconvulsive type, which is characterized by dizziness, apathy, and unresponsiveness. The seizures can cause sudden falling (or spasms in tonic, atonic and myoclonic episodes) and/or loss of balance, which is why patients often wear a helmet to prevent head injury.

In addition to daily multiple seizures of various types, children with LGS frequently have arrested/slowed psycho-motor development and behavior disorders.

The syndrome is also characterized by an interictal (between-seizures) EEG featuring slow spike-wave complexes.

Incidence and prevalence[edit]

LGS is seen approximately 4% of children with epilepsy, and is more prevalent in males than females. [2] Children can have no neurological problems prior diagnosis, or have other forms of epilepsy. West syndrome is diagnosed in 20% of patients before it evolves into LGS at about 2 years old.[3]

Finland[edit]

According to a 1997 community-based retrospective study in the Helsinki metropolitan area and the province of Uusimaa, the annual incidence of Lennox–Gastaut was 2 in 100,000 (0.002%) from 1975 to 1985.[4]

United States[edit]

0.026% of all children in the Atlanta, Georgia metropolitan area were estimated to have LGS in 1997, which was defined as, "onset of multiple seizure types before age 11 years, with at least one seizure type resulting in falls, and an EEG demonstrating slow spike-wave complexes (<2.5 Hz)." The study concluded that LGS accounts for 4% of childhood epilepsies.[2]

Mortality[edit]

The mortality rate ranges from 3-7% in a mean follow up period of 8.5 to 9.7 years. Death is often related to accidents.[5]

Causes[edit]

There is no uniform cause: in 20% of those concerned, the LGS develops from West syndrome.[3] The medical history frequently includes infantile spasms or focal and generalized seizures.

The most common type of LGS (70–78%) is symptomatic (secondary) - that is an identifiable underlying pathology is responsible.[2] This includes encephalopathy (brain damage) or another disease and/or developmental disorder. Frequent causes include tuberous sclerosis, hereditary metabolic diseases, inflammatory brain disease such as encephalitis, meningitis, and toxoplasmosis; hypoxiaischemia injury and other birth injuries; and lesions of the frontal lobe. These patients tend to have a worse prognosis than those with idiopathic LGS.[3]

In up to one-third of cases no cause can be found.[3] These cases are referred as cryptogenic if a cause is suspected but unknown. Not all investigators mention the second category.

Lennox–Gastaut syndrome and drug resistant/drug refractory epilepsy have been recorded with neurovisceral porphyrias including acute intermittent porphyria, hereditary coproporphyria and variegate porphyria. Care must be taken to avoid porphyrinogenic anti-seizure drugs in these cases. Diagnosis may be difficult in children who require enzyme or DNA testing.

Diagnosis[edit]

Generally speaking, LGS can often only be defined as a syndrome and/or distinguished from other syndromes because there are various overlaps with other syndromes. Currently, the fact that there is no uniform cause complicates things.


The diagnosis or suspicion of LGS is often a question of probability rather than certainty. This is because the varied presentations of LGS share features with other disorders, many of which may be said to have overlapping characteristics.

The diagnosis is more obvious when the epilepsy has frequent and manifold attacks, with the classic pattern on the electro-encephalogram (EEG); the latter is a slowed rhythm with Spike-wave-pattern, or with a multifocal and generalizing Sharp-slow-wave-discharges at 1.5–2.5 Hz. During sleep, frequently, tonic patterns can be seen. But variations of these patterns are known in patients with no diagnosis other than LGS, and they can differ bilaterally, and from time to time, within the same patient.

General medical investigation usually reveals developmental delay and cognitive deficiencies in children with true LGS. These may precede development of seizures, or require up to two years after the seizures begin, in order to become apparent.

Exclusion of organic or structural brain lesions is also important in establishing a correct diagnosis of LGS; this may require magnetic resonance imaging (MRI) or computerized tomography (CT). An important differential diagnosis is 'Pseudo-Lennox-Syndrome', which differs from LGS, in that there are no tonic seizures; sleeping EEG provides the best basis for distinguishing between the two.

Treatment[edit]

LGS seizures are often treatment resistant, but this does not mean that treatment is futile. Options include anticonvulsants, anesthetics, steroids such as prednisone, immunoglobulins, and various other pharmacological agents that have been reported to work in individual patients.

Pharmacological[edit]

No scientific study has shown any drug to be highly efficacious for treatment of LGS, and its best treatment remains uncertain. Rufinamide(Banzel), lamotrigine, topiramate and felbamate may help as add-on therapy.[6]

Approved[edit]

First-line drugs[edit]

Rufinamide approved recently by FDA

Nitrazepam is not approved in the USA.

Clobazam has been recently approved by the FDA on 10/24/11.

Second-line drugs[edit]

In 1999, Dr. Sachdeo and colleagues at the University of Medicine and Dentistry of New Jersey and the Robert Wood Johnson Medical School in New Brunswick reported that 33% of the patients in the topiramate group experienced a minimum 50% reduction in seizures (specifically drop attacks and tonic–clonics), compared with 8% in the placebo group.[7] It was also found to be effective as an adjunctive therapy in a review published by Drs. Edith Alva Moncayo and Antonio Ruiz Ruiz in March 2003.[8]

Dr. Motte and colleagues at the American Memorial Hospital at Reims, France reported in 1997 that lamotrigine was effective in the treatment of LGS, with the most common side effect in the treatment group relative to placebo being colds or viral illnesses.[9] Two years later, it was approved by Health Canada for adjunctive therapy in Lennox Gastaut in adults and children.[10] The United States Food and Drug Administration approved it for that in August 1998.[11]

Felbamate is indicated in the use of LGS in the event that everything else fails,[12] and was found to be superior to placebo in controlling treatment resistant partial seizures and atonic seizures.[13][14] However, it has been known to cause aplastic anemia and liver toxicity.[15]

Unapproved, off-label, and investigational drugs[edit]

Vigabatrin was found by Feucht et al. to be an effective add-on in patients whose seizures were not satisfactorily controlled by valproate. Out of 20 children, only 1 experienced a serious side effect (dyskinesia).[16]

Zonisamide showed promise in an overview of controlled and uncontrolled trials conducted in Japan.[17] However, in a physician survey conducted December 2004, only 28% of Lennox–Gastaut and West syndrome patients improved on zonisamide.[18]

Surgical[edit]

Other[edit]

Ketogenic diet[edit]

Main article: Ketogenic diet

A ketogenic diet is a diet that causes ketosis, a state in which there is an increased amount of ketones in the body. It is becoming increasingly popular for treating intractable epilepsy.

Intravenous immunoglobulin therapy[edit]

Intravenous immunoglobulin therapy has been used in Lennox–Gastaut syndrome as early as 1986, when van Rijckevorsel-Harmant and colleagues used it in seven patients with ostensibly idiopathic LGS and saw EEG improvement and decreased seizure frequency in six of them.[19]


History[edit]

LGS was named for neurologists William G. Lennox (Boston, USA) and Henri Gastaut (Marseille, France).

In 2010 the first documentary highlighting this disorder was produced by Eisai Inc. in cooperation with the LGS Foundation.

http://www.livingwithlgs.com/lgs-documentary.aspx

Support[edit]

Caregivers of individuals living with Lennox-Gastaut Syndrome may seek support and information from a variety of resources including the LGS Foundation and the Epilepsy Foundation of America. The LGS Foundation offers regional support groups across the United States and numerous programs and services.

Resources[edit]

LGS Foundation [1]
Epilepsy.com [2]
Epilepsy Foundation [3]

References[edit]

  1. ^ "Childhood seizures – epilepsy and convulsions in children". Archived from the original on April 8, 2005. Retrieved August 16, 2005. 
  2. ^ a b c Trevathan, E; Murphy, CC; Yeargin-Allsopp, M (1997). "Prevalence and descriptive epidemiology of Lennox-Gastaut syndrome among Atlanta children". Epilepsia 38 (12): 1283–8. doi:10.1111/j.1528-1157.1997.tb00065.x. PMID 9578523. 
  3. ^ a b c d Tyagi, Satyanand et al (July–Sept 2010). "Pharmacological Management of Lennox-Gastaut Syndrome a Difficult to Treat Form of Childhood-Onset Epilepsy: An Overview". International Journal of Pharma and Bio Sciences 1 (3): 1–6.  Check date values in: |date= (help)
  4. ^ Heiskala, H (1997). "Community-based study of Lennox-Gastaut syndrome". Epilepsia 38 (5): 526–31. doi:10.1111/j.1528-1157.1997.tb01136.x. PMID 9184597. 
  5. ^ Glauser, Tracy A. and Morita, Diego A. (2002). "Introduction". Lennox–Gastaut Syndrome. eMedicine.com, Inc. Retrieved 8 July 2005. 
  6. ^ Hancock, EC; Cross, HH; Hancock, Eleanor C (2009). Hancock, Eleanor C, ed. "Treatment of Lennox-Gastaut syndrome". Cochrane database of systematic reviews (Online) (3): CD003277. doi:10.1002/14651858.CD003277.pub2. PMID 19588340. 
  7. ^ Sachdeo, R. C.; Glauser, TA; Ritter, F; Reife, R; Lim, P; Pledger, G (1999). "A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome". Neurology 52 (9): 1882–7. doi:10.1212/wnl.52.9.1882. PMID 10371538. 
  8. ^ Alva-Moncayo, E; Ruiz-Ruiz, A (2003). "Utilidad del topiramato como terapia añadida a esquemas convencionales para el síndrome de Lennox-Gastaut" [The value of topiramate used with conventional schemes as an adjunctive therapy in the treatment of Lennox-Gastaut syndrome]. Revista de neurologia (in Spanish) 36 (5): 453–7. PMID 12640599. 
  9. ^ Motte, J; Trevathan, E; Arvidsson, JF; Barrera, MN; Mullens, EL; Manasco, P (1997). "Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. Lamictal Lennox-Gastaut Study Group". The New England Journal of Medicine 337 (25): 1807–12. doi:10.1056/NEJM199712183372504. PMID 9400037. 
  10. ^ Epilepsy Ontario (1999). "Lamotrigine Approved in Canada for Lennox–Gastaut Syndrome". 'Sharing' News. Retrieved 13 November 2005. 
  11. ^ Glaxo Wellcome Inc (1998). "Final Printed Labeling—Part 1". Lamictal Tablets & Chewable Dispersible Tablets (Lamotrigine) Drug Approval Page. United States Food and Drug Administration Center for Drug Evaluation and Research. Retrieved 13 November 2005. [dead link]
  12. ^ "Felbatol (felbamate)". p. 3. Retrieved 2007-09-19. 
  13. ^ The Felbamate Study Group In Lennox-gastaut Syndrome (1993). "Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome). The Felbamate Study Group in Lennox-Gastaut Syndrome". The New England Journal of Medicine 328 (1): 29–33. doi:10.1056/NEJM199301073280105. PMID 8347179. 
  14. ^ Devinsky, O; Faught, RE; Wilder, BJ; Kanner, AM; Kamin, M; Kramer, LD; Rosenberg, A (1995). "Efficacy of felbamate monotherapy in patients undergoing presurgical evaluation of partial seizures". Epilepsy research 20 (3): 241–6. doi:10.1016/0920-1211(94)00084-A. PMID 7796796. 
  15. ^ O'neil, MG; Perdun, CS; Wilson, MB; Mcgown, ST; Patel, S (1996). "Felbamate-associated fatal acute hepatic necrosis". Neurology 46 (5): 1457–9. doi:10.1212/wnl.46.5.1457. PMID 8628501. 
  16. ^ Feucht, M; Brantner-Inthaler, S (1994). "Gamma-vinyl-GABA (vigabatrin) in the therapy of Lennox-Gastaut syndrome: an open study". Epilepsia 35 (5): 993–8. doi:10.1111/j.1528-1157.1994.tb02544.x. PMID 7925171. 
  17. ^ Yagi, K (2004). "Overview of Japanese experience-controlled and uncontrolled trials". Seizure : the journal of the British Epilepsy Association. 13 Suppl 1: S11–5; discussion S16. doi:10.1016/j.seizure.2004.04.018. PMID 15511680. 
  18. ^ Yamauchi, T; Aikawa, H (2004). "Efficacy of zonisamide: our experience". Seizure : the journal of the British Epilepsy Association. 13 Suppl 1: S41–8; discussion S49. doi:10.1016/j.seizure.2004.04.021. PMID 15511689. 
  19. ^ Van Rijckevorsel-Harmant, K; Delire, M; Rucquoy-Ponsar, M (1986). "Treatment of idiopathic West and Lennox-Gastaut syndromes by intravenous administration of human polyvalent immunoglobulins". European archives of psychiatry and neurological sciences 236 (2): 119–22. doi:10.1007/BF00454021. PMID 3792407. 

See also[edit]


Original courtesy of Wikipedia: http://en.wikipedia.org/wiki/Lennox–Gastaut_syndrome — Please support Wikipedia.
This page uses Creative Commons Licensed content from Wikipedia. A portion of the proceeds from advertising on Digplanet goes to supporting Wikipedia.
2082 videos foundNext > 

Lennox Gastaut Syndrome (multiple seizures and autistic)

Sometimes, when it happen, he just want to challenge it, he sometimes even make a fun of his seizures and lough at himself. He is Autistic and diagnosed with...

Charlie's Story - Lennox-Gastaut Syndrome

Lennox Gastaut Syndrome is a devastating form of epilepsy that affects thousands of children. Charlie's experience offers hope, he has gone through the illne...

Lennox-Gastaut Syndrome

Made this short video upon request for LGS day on November 1st.

Lennox Gastaut Syndrome ( 2 Types of Seizures and Autism)

This little 6 years old boy has numerous daily seizures starring spell and head drop resulting from Traumatic Head and brain injury, suffers from autism as w...

Emilia Hernández sindrome Lennox Gastaut

Convulsion de mas de 3 minutos, con espasmos y ausencias.

Lennox Gastaut Syndrome

Heather Rileys journey over the last year from brain surgery to IVIG. You never know what tomorrow holds, Heather has taught us to enjoy each moment as it co...

Lennox-Gastaut Syndrome

Reviews the EEG in Lennox-Gastaut Syndrome.

How did a neuroscientist ameliorate seizures in her daughter's Lennox-Gastaut syndrome?

In this video segment, Neurology Today's Editor-in-Chief Steven P. Ringel, MD, talks with Tracy Dixon-Salazar, PhD, associate research director at Citizens U...

Epilepsy Therapy Project Presents: Lennox-Gastaut Syndrome Roundtable - Dr. Randa Jarrar

Dr. Jarrar is a Pediatric Epileptologist at Phoenix Children's Hospital. She is going to be discussing diagnosis, the issues of the larger spectrum of issues...

The KannonBall WOD for Lennox Gastaut Syndrome

This video was created to raise awareness for Lennox Gastaut Syndrome. We have teamed up with several Crossfit gyms across the state of Oklahoma to help in o...

2082 videos foundNext > 

97 news items

Motley Fool

Motley Fool
Fri, 31 Oct 2014 09:52:30 -0700

... for use in certain epilepsy patients. However, a cancer pain approval would be for second line use only behind opioids and the two epilepsy conditions GW Pharma is studying, Dravet and Lennox-Gastaut Syndrome are rare with small patient populations.
 
Atlanta Journal Constitution (blog)
Thu, 30 Oct 2014 12:01:53 -0700

This is one of the many consequences of the “medical refugee” life we have to live in order to heal our child. Chris Clark is a sergeant with the Atlanta Police Department. His son Caden, 11, suffers from Lennox Gastaut Syndrome, a rare and often ...

Houston Chronicle

Nasdaq
Thu, 30 Oct 2014 05:33:45 -0700

Furthermore, two phase 3 clinical trials in Lennox-Gastaut syndrome will also be launched in Q1 2015. Shares in the company were trading 1.28% higher at $71 during Thursday's pre-market trading session. Over the past 52 weeks, the company has traded ...

Scottish Daily Record

Scottish Daily Record
Wed, 29 Oct 2014 17:20:35 -0700

Max McGhie, from St Leonards, suffers from Lennox-Gastaut Syndrome, a rare and devastating form of epilepsy. The drug resistant condition meant 14-year-old Max suffered from multiple seizures every day of his life ... any one of which could have proved ...
 
PR Newswire (press release)
Tue, 14 Oct 2014 13:20:35 -0700

... and Drug Administration (FDA) has accepted the company's sNDA for rufinamide and granted it priority review designation as an adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome (LGS) in pediatric patients from 1 to 4 years of age.
 
Sunbury Daily Item
Mon, 27 Oct 2014 20:01:29 -0700

Along with Folmer, also speaking was Cristy Harding, the Turbotville ER nurse and mother of Jason, 14, who has a severe seizure disorder called Lennox-Gastaut syndrome that would respond to medical marijuana. Harding's portion was a myth vs. fact ...
 
MicroCap Daily
Tue, 28 Oct 2014 08:30:04 -0700

... by the EMA, GW has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for Epidiolex in the treatment of Dravet syndrome as well as orphan designations in both Dravet syndrome and Lennox-Gastaut syndrome (LGS).
 
Medscape
Wed, 22 Oct 2014 10:26:15 -0700

... syndrome, and etiology provides a basis for responding to the important question of prognosis. For example, children with benign rolandic epilepsy invariably outgrow this disorder by their teenage years, whereas those with Lennox-Gastaut syndrome ...
Loading

Oops, we seem to be having trouble contacting Twitter

Support Wikipedia

A portion of the proceeds from advertising on Digplanet goes to supporting Wikipedia. Please add your support for Wikipedia!

Searchlight Group

Digplanet also receives support from Searchlight Group. Visit Searchlight